Ancient Proteins Help Unravel a Modern Cancer Drug’s Mechanism

The cancer drug Gleevec is extremely specific, binding and inhibiting only the cancer-causing tyrosine protein kinase Blc-Abl, while not targeting homologous protein kinases found in normal, healthy cells. Researchers at the ALS have uncovered exactly why that is the case, pointing to novel methods of drug discovery.